Altimmune, Inc. (ALT)

Altimmune Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-88.45	-84.71	-97.09	-49.04	-20.97
Depreciation & Amortization	0.48	0.49	0.55	0.43	0.39
Share-Based Compensation	10.64	8.1	5.52	2.58	1.26
Other Operating Activities	1.52	13.53	12.78	11.73	9.27
Operating Cash Flow	-75.81	-62.59	-78.24	-34.31	-9.6
Capital Expenditures	-0.05	-0.13	-12.12	-0.2	-0
Change in Investments	13.78	-73.27	99.84	-71.88	-28.26
Other Investing Activities	-	-	-0.2	-0.14	-0.03
Investing Cash Flow	13.73	-73.4	87.52	-72.23	-28.29
Share Issuance / Repurchase	86.93	57.3	65.22	213.49	12.7
Debt Issued / Paid	0	0	0	0	-0.29
Other Financing Activities	-0.82	-0.52	-0.12	-	0.13
Financing Cash Flow	86.11	56.78	65.1	213.49	12.53
Net Cash Flow	24.03	-79.2	74.38	106.96	-25.36
Free Cash Flow	-75.86	-62.71	-90.36	-34.51	-9.6
Free Cash Flow Margin	-17806.81%	-	-2048.87%	-421.62%	-165.53%
Free Cash Flow Per Share	-1.43	-1.34	-2.19	-1.35	-0.73

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).